The global emergency contraceptive pills market size reached USD 606.4 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 826.5 Million by 2033, exhibiting a growth rate (CAGR) of 3.33% during 2025-2033. The increasing awareness among the masses regarding contraception and family planning, the implementation of supportive policies by governments and non-governmental organizations (NGOs), and the recent development of non-hormonal ECPs represent some of the key factors driving the market.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 606.4 Million |
Market Forecast in 2033 | USD 826.5 Million |
Market Growth Rate (2025-2033) | 3.33% |
Emergency contraceptive pills (ECPs) refer to birth control medications used for preventing unwanted pregnancies. They are manufactured using synthetic hormones, such as levonorgestrel, which delays ovulation, changes the linings of the uterus, and prevents egg fertilization. ECPs are widely used during the failure of traditional methods of contraception, after unprotected sexual intercourse, as a backup for missing routine birth control pills, and by the victims of sexual assault crimes. They are safe, cost-effective, accessible, and highly convenient medications that do not cause long-term fertility issues, successfully prevent unintended pregnancies, and eliminate the need for abortions. ECPs also provide better control over reproductive health, empower women, reduce anxiety and stress, and minimize side effects.
The increasing awareness among the masses regarding contraception and family planning is one of the key factors propelling the market growth. ECPs are widely used by women as a safe, convenient, and highly comfortable form of emergency contraception, which prevents unwanted pregnancies, maintains privacy, and minimizes the risks of side effects and future complications. Along with this, the widespread product utilization due to rising incidences of unintended pregnancies owing to unprotected intercourse and sexual assault is acting as another growth-inducing factor. Furthermore, the implementation of supportive policies by governments and non-governmental organizations (NGOs) to spread awareness, educate the masses, and provide easy access to emergency contraception is positively influencing the market growth. Additionally, the recent development of non-hormonal ECPs, which contains ulipristal acetate that blocks progesterone receptors in the body and produces fewer side effects compared to traditional levonorgestrel-based pills, is providing an impetus to the market growth. Apart from this, the rising product adoption owing to the increasing focus on women's health and well-being across the globe is favoring the market growth. Besides this, the growing demand for over-the-counter (OTC) products that don't require prescriptions and can be easily accessed by women in case of emergency is supporting the market growth. Moreover, aggressive promotional and branding campaigns by manufacturers through social media, influencer marketing, television (TV) commercials, and celebrity endorsement are contributing to the market growth. Other factors, including rising expenditure capacities of consumers, extensive research and development (R&D) activities, and easy product availability across e-commerce platforms, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global emergency contraceptive pills market, along with forecasts at the global, regional, and country levels from 2025-2033. Our report has categorized the market based on type and distribution channel.
Type Insights:
The report has provided a detailed breakup and analysis of the emergency contraceptive pills market based on the type. This includes combination pills, progesterone pills, and others. According to the report, combination pills represented the largest segment.
Distribution Channel Insights:
A detailed breakup and analysis of the emergency contraceptive pills market based on the distribution channel has also been provided in the report. This includes retail stores, online stores, and others. According to the report, retail stores accounted for the largest market share.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for emergency contraceptive pills. Some of the factors driving the North America emergency contraceptive pills market included the increasing awareness regarding women’s health, supportive government policies, and significant technological advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global emergency contraceptive pills market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Afaxys Pharma LLC, Foundation Consumer Healthcare LLC, Gedeon Richter Plc, HLL Lifecare Limited, Perrigo Company plc, Piramal Enterprises Ltd., Syzygy Healthcare Solutions LLC, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Types Covered | Combination Pills, Progesterone Pills, Others |
Distribution Channels Covered | Retail Stores, Online Stores, Others |
Regions Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Afaxys Pharma LLC, Foundation Consumer Healthcare LLC, Gedeon Richter Plc, HLL Lifecare Limited, Perrigo Company plc, Piramal Enterprises Ltd., Syzygy Healthcare Solutions LLC, etc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |